Lilly Completes Acquisition of Applied Molecular Evolution

16-Feb-2004

Eli Lilly and Company announced that the company completed its acquisition of Applied Molecular evolution, Inc. (AME), whereby AME became a wholly owned subsidiary of Lilly. The acquisition was previously announced in Nov. 2003, and was approved by AME stockholders at a special meeting in Feb. 2004.

AME stockholders will receive $18 for each AME share in the form of cash, Lilly common stock or a combination of cash and Lilly common stock, based on elections made by AME stockholders and subject to the proration and adjustment mechanisms of the merger agreement. Today's closing price of Lilly common stock of $73.58 per share results in an exchange ratio of 0.2446 of a Lilly share per AME share for those AME stockholders receiving the stock consideration.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances